Key Points
- CEO Clay Siegall purchased 4,729 shares on December 30 at an average price of $21.15 for about $100,018, raising his direct stake to 665,254 shares (a 0.72% increase).
- Immunome stock is trading near $21 with a $1.94B market cap, recently reported a quarterly EPS loss that missed estimates and carries deeply negative margins, while analysts hold a consensus "Moderate Buy" rating with an average price target of $30.09.
- Immunome is a clinical-stage biotech developing antibody-based therapeutics, with its lead oncology program IMM-BCP-01 currently in early-stage trials targeting breast cancer antigens.
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) CEO Clay Siegall acquired 4,729 shares of the business's stock in a transaction dated Tuesday, December 30th. The shares were bought at an average price of $21.15 per share, with a total value of $100,018.35. Following the transaction, the chief executive officer directly owned 665,254 shares in the company, valued at approximately $14,070,122.10. The trade was a 0.72% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Immunome Stock Down 1.9%
IMNM opened at $21.18 on Wednesday. The stock has a fifty day moving average of $18.54 and a 200-day moving average of $13.35. The firm has a market capitalization of $1.94 billion, a P/E ratio of -7.18 and a beta of 2.17. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $25.30.
Immunome (NASDAQ:IMNM - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. On average, analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on IMNM shares. Wedbush reiterated an "outperform" rating and set a $21.00 target price on shares of Immunome in a research report on Friday, November 7th. Guggenheim raised their price objective on shares of Immunome from $25.00 to $35.00 and gave the company a "buy" rating in a research report on Tuesday, December 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immunome in a research note on Wednesday, October 8th. Truist Financial began coverage on Immunome in a report on Monday, December 1st. They set a "buy" rating and a $36.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a report on Saturday, November 22nd. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Immunome has an average rating of "Moderate Buy" and a consensus price target of $30.09.
Read Our Latest Research Report on IMNM
Hedge Funds Weigh In On Immunome
Several institutional investors and hedge funds have recently added to or reduced their stakes in IMNM. Assetmark Inc. acquired a new stake in shares of Immunome in the third quarter valued at about $39,000. BNP Paribas Financial Markets increased its stake in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock valued at $60,000 after purchasing an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after buying an additional 3,802 shares during the period. BIT Capital GmbH bought a new position in shares of Immunome in the 3rd quarter worth $69,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Immunome in the third quarter valued at $76,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.
Immunome Company Profile
(
Get Free Report)
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
